Condition: Non-segmental Vitiligo · Sponsor: Elixiron Immunotherapeutics (Hong Kong) Ltd.
The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Marvel Clinical Research | Huntington Beach, California, United States | Recruiting |
| Skin Care Research, LLC | Hollywood, Florida, United States | Recruiting |
| U Mass Chan Medical School | Worcester, Massachusetts, United States | Withdrawn |
| Apex Clinical Research Center, LLC (Mayfield) | Mayfield Heights, Ohio, United States | Recruiting |
| Center for Clinical Studies | Houston, Texas, United States | Recruiting |
| Linkou Chang Gung Memorial Hospital | Taoyuan, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07223229